Fibrosis
Fibrosis is a pathological process in which persistent tissue injury, inflammation, or cellular stress promotes activation of fibroblasts and excessive deposition of extracellular matrix components, particularly collagen.
Fibrosis is a pathological process in which persistent tissue injury, inflammation, or cellular stress promotes activation of fibroblasts and excessive deposition of extracellular matrix components, particularly collagen. Progressive collagen accumulation can distort tissue architecture and impair organ function. In the liver, fibrosis is a major feature of metabolic dysfunction–associated steatohepatitis (MASH), which develops in the setting of metabolic dysfunction–associated steatotic liver disease, hepatic steatosis, oxidative stress, and liver injury. Fibrosis staging ranges from none or mild disease (F0/F1) through moderate (F2) and severe or advanced fibrosis (F3/F4); assessment may involve histology, serum-based risk measures such as Fibrosis-4, magnetic resonance elastography, and combined elastography–ultrasound approaches.
Current research treats fibrosis as both a clinical risk marker and a therapeutic target. In MASH, studies have examined metabolic and inflammatory pathways including PPARα/CCL2 signaling, fatty-acid metabolism, and AOAH-mediated lipopolysaccharide handling in macrophages and Kupffer cells. Other disease-specific investigations have evaluated HIF-1α inhibition by digoxin in thyroid eye disease, engineered mesenchymal stem cells that regulate the integrated stress response, and combinations designed to target fibrosis in cancer. These approaches extend efforts to integrate noninvasive liver fibrosis risk stratification into diabetes care while exploring pathway-directed, immune, and cellular therapies across distinct fibrotic diseases.
Where the papers sit
11 papers from the last 6 months study fibrosis directly · updated from PubMed 8 Nov 2026
Study type 0 clinical trials · 2 observational · 1 human data · 3 preclinical · 5 unclassified
Themes 3 themes
-
MASLD Fibrosis Assessment
MASLD care is moving toward integrated, non-invasive fibrosis risk stratification in people with diabetes. Magnetic resonance elastography, Fibrosis-4, LITMUS testing, and deep-learning elastography aim to replace or reduce biopsy dependence. Pharmacist-led screening embeds risk assessment within diabetes care. Luseogliflozin added to semaglutide extends this approach from staging toward combined metabolic and liver-directed treatment.
5 papers · 45.5%
-
Inflammatory Fibrosis Pathways
PPARα/CCL2 signaling links lipid metabolism to inflammatory fibrosis in MASH. Lipidated amino acid deficiency and altered fatty acid oxidation emerge as targets for restoring this axis. In thyroid eye disease, digoxin acts through HIF-1α inhibition to reduce inflammation and fibrosis. The work is moving toward pathway-specific antifibrotic interventions rather than nonspecific suppression.
2 papers · 18.2%
-
Others — Fibrosis and Cellular Therapeutics
Macrophage endotoxin tolerance, engineered MSCs, NKG2D-CAR T cells, and trichrome-based deep learning appear together without a unified biological question. MASH studies focus on AOAH-mediated LPS inactivation and quantitative pathology. Separate work targets integrated stress response in fibrosis or NKG2D-CAR T activity in breast cancer. The cluster therefore has no defensible shared therapeutic trajectory.
4 papers · 36.4%
Papers
The 11 papers from the last 6 months that study fibrosis directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
MASLD Fibrosis Assessment (5)
- Non-invasive tests in metabolic dysfunction-associated steatotic liver disease: the LITMUS prospective multicentre diagnostic accuracy study. Lancet (London, England) · 29 Oct 2026 PMID 42956772
- Embedding metabolic dysfunction-associated steatotic liver disease fibrosis risk stratification within pharmacist-integrated diabetes comanagement in primary care. Journal of managed care & specialty pharmacy · 29 Sept 2026 PMID 42808546
- Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial. Diabetes, obesity & metabolism · 17 Aug 2026 PMID 42605535
- Simplified definition and imaging-based stratification of at-risk MASH using magnetic resonance elastography. Hepatology communications · 11 Aug 2026 PMID 42579768
- A combi-elasto ultrasound based deep learning model on liver fibrosis staging for suspected MASLD/MASH patients. BMC medical imaging · 18 Jul 2026 PMID 42471585
Inflammatory Fibrosis Pathways (2)
- Targeting lipidated amino acid deficiency mitigates fibrosis via a PPARα/CCL2 axis in metabolic dysfunction-associated steatohepatitis models. The Journal of clinical investigation · 24 Sept 2026 PMID 42784330
- Digoxin inhibits HIF-1α to attenuate inflammation and fibrosis in thyroid eye disease. Biochemical and biophysical research communications · 24 Jul 2026 PMID 42497831
Others — Fibrosis and Cellular Therapeutics (4)
- Trichrome-based deep learning for quantitative assessment of steatosis, hepatocellular ballooning, and fibrosis in metabolic dysfunction-associated steatohepatitis. Virchows Archiv : an international journal of pathology · 6 Nov 2026 PMID 42995264
- AOAH-mediated LPS inactivation limits macrophage endotoxin tolerance and promotes inflammation and fibrosis in MASH. Cellular and molecular gastroenterology and hepatology · 29 Aug 2026 PMID 42668090
- Engineered mesenchymal stem cells regulate integrated stress response for fibrosis therapy. Med (New York, N.Y.) · 12 Aug 2026 PMID 42586072
- All-trans retinoic acid and lansoprazole potentiated NKG2D-CAR T for breast cancer treatment. International immunopharmacology · 20 May 2026 PMID 42161056
By study type
Observational studies and case reports (2)
- Non-invasive tests in metabolic dysfunction-associated steatotic liver disease: the LITMUS prospective multicentre diagnostic accuracy study. Lancet (London, England) · 29 Oct 2026 PMID 42956772
- Simplified definition and imaging-based stratification of at-risk MASH using magnetic resonance elastography. Hepatology communications · 11 Aug 2026 PMID 42579768
Human data, design not indexed (1)
- Embedding metabolic dysfunction-associated steatotic liver disease fibrosis risk stratification within pharmacist-integrated diabetes comanagement in primary care. Journal of managed care & specialty pharmacy · 29 Sept 2026 PMID 42808546
Preclinical: animal, cell and lab studies (3)
- Engineered mesenchymal stem cells regulate integrated stress response for fibrosis therapy. Med (New York, N.Y.) · 12 Aug 2026 PMID 42586072
- Digoxin inhibits HIF-1α to attenuate inflammation and fibrosis in thyroid eye disease. Biochemical and biophysical research communications · 24 Jul 2026 PMID 42497831
- All-trans retinoic acid and lansoprazole potentiated NKG2D-CAR T for breast cancer treatment. International immunopharmacology · 20 May 2026 PMID 42161056
Unclassified: not yet indexed with MeSH (5)
- Trichrome-based deep learning for quantitative assessment of steatosis, hepatocellular ballooning, and fibrosis in metabolic dysfunction-associated steatohepatitis. Virchows Archiv : an international journal of pathology · 6 Nov 2026 PMID 42995264
- Targeting lipidated amino acid deficiency mitigates fibrosis via a PPARα/CCL2 axis in metabolic dysfunction-associated steatohepatitis models. The Journal of clinical investigation · 24 Sept 2026 PMID 42784330
- AOAH-mediated LPS inactivation limits macrophage endotoxin tolerance and promotes inflammation and fibrosis in MASH. Cellular and molecular gastroenterology and hepatology · 29 Aug 2026 PMID 42668090
- Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial. Diabetes, obesity & metabolism · 17 Aug 2026 PMID 42605535
- A combi-elasto ultrasound based deep learning model on liver fibrosis staging for suspected MASLD/MASH patients. BMC medical imaging · 18 Jul 2026 PMID 42471585
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-10-02. Drafted by language models from published abstracts; not medical advice.